BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aasen SN, Parajuli H, Hoang T, Feng Z, Stokke K, Wang J, Roy K, Bjerkvig R, Knappskog S, Thorsen F. Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. Int J Mol Sci 2019;20:E4235. [PMID: 31470659 DOI: 10.3390/ijms20174235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Deb B, Sengupta P, Sambath J, Kumar P. Bioinformatics Analysis of Global Proteomic and Phosphoproteomic Data Sets Revealed Activation of NEK2 and AURKA in Cancers. Biomolecules 2020;10:E237. [PMID: 32033228 DOI: 10.3390/biom10020237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
3 Xing J, Yang J, Gu Y, Yi J. Research update on the anticancer effects of buparlisib. Oncol Lett 2021;21:266. [PMID: 33717263 DOI: 10.3892/ol.2021.12527] [Reference Citation Analysis]
4 Wanleenuwat P, Iwanowski P. Metastases to the central nervous system: Molecular basis and clinical considerations. J Neurol Sci 2020;412:116755. [PMID: 32120132 DOI: 10.1016/j.jns.2020.116755] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, Fukumura D, Gril B, Herlyn M, Holmen SL, Jain RK, Joyce JA, Lorger M, Massague J, Neman J, Sibson NR, Steeg PS, Thorsen F, Young LS, Varešlija D, Vultur A, Weis-Garcia F, Winkler F. Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Res 2020;80:4314-23. [PMID: 32641416 DOI: 10.1158/0008-5472.CAN-20-0291] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
6 Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers (Basel) 2021;13:1685. [PMID: 33918490 DOI: 10.3390/cancers13071685] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Djanani A, Eller S, Öfner D, Troppmair J, Maglione M. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Int J Mol Sci 2020;21:E9001. [PMID: 33256240 DOI: 10.3390/ijms21239001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, Garrett JT. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel) 2020;12:E482. [PMID: 32092958 DOI: 10.3390/cancers12020482] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
9 Miao Y, Zhang W, Liu S, Leng X, Hu C, Sun H. HOXC10 promotes growth and migration of melanoma by regulating Slug to activate the YAP/TAZ signaling pathway. Discov Oncol 2021;12:12. [PMID: 35201457 DOI: 10.1007/s12672-021-00408-7] [Reference Citation Analysis]
10 Sun T, Zhang J, Deng B, Fan X, Long T, Jin H, Tao S, Kang P, Tan Q. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim. Acta Biochimica et Biophysica Sinica 2020;52:1348-59. [DOI: 10.1093/abbs/gmaa129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Johnson DB, Nebhan CA, Noel MS. MEK inhibitors in non-V600 BRAF mutations and fusions. Oncotarget 2020;11:3900-3. [PMID: 33216832 DOI: 10.18632/oncotarget.27788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Koroknai V, Patel V, Szász I, Ádány R, Balazs M. Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids. Pathol Oncol Res 2020;26:2557-66. [PMID: 32613561 DOI: 10.1007/s12253-020-00837-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Shin S, Lee JS, Joo BJ, Ryu G, Han M, Kim H, An J, Koo MH, Youn UJ, Lee JH, Park HH, Lee CS. Anti-cancer effects of lucidadiol against malignant melanoma cells. Appl Biol Chem 2021;64. [DOI: 10.1186/s13765-021-00647-w] [Reference Citation Analysis]
14 Boos LA, Leslie I, Larkin J. Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opin Investig Drugs 2020;29:739-53. [PMID: 32401070 DOI: 10.1080/13543784.2020.1769066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hu J, Wei J, Yim H, Wang L, Xie L, Jin MS, Kabir M, Qin L, Chen X, Liu J, Jin J. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. J Med Chem 2020;63:15883-905. [PMID: 33284613 DOI: 10.1021/acs.jmedchem.0c01609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Tan B, Yuan Z, Zhang Q, Xiqiang X, Dong J. The NF-κB pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells. J Appl Biomed 2021;19:190-201. [PMID: 34907738 DOI: 10.32725/jab.2021.021] [Reference Citation Analysis]